Amarin shares fall 10% as patent wrangling continues, but analysts remain confident
This article was originally published in Scrip
Executive Summary
Shares in Irish biotech Amarin fell nearly 10% on 2 March, as the US Patent and Trademark Office (PTO) issued yet another non-final rejection for one of Amarin's 16 patent applications. The company filed a note with the SEC highlighting its continuing struggle to gain use patents for its lead candidate AMR101, which it has filed in the US as a treatment for patients with very high triglycerides.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.